Abstract: Compositions and methods disclosed concern an isogenic population of in vitro human embryonic stem cells comprising a disease form of the Huntingtin gene (HTT) at the endogenous HTT gene locus in the genome of the cell; wherein the disease form of the HTT gene comprises a polyQ repeat of at least 40 glutamines at the N-terminus of the Huntingtin protein (HTT). The cell lines of the disclosure comprise genetically-defined alterations made in the endogenous HTT gene that recapitulate Huntington's Disease in humans. Furthermore, the cell lines have isogenic controls that share a similar genetic background. Differentiating cell lines committed to a neuronal fate and fully differentiated cell lines are also provided and they also display phenotypic abnormalities associated with the length of the polyQ repeat of the HTT gene. These cell lines are used as screening tools in drug discovery and development to identify substances that fully or partially revert these phenotype abnormalities.
Type:
Application
Filed:
February 24, 2017
Publication date:
June 27, 2019
Applicant:
The Rockefeller University
Inventors:
Ali BRIVANLOU, Albert RUZO, Alessia DEGLINCERTI, Tomomi HAREMAKI, Fred ETOC
Abstract: An optical system for the detection of skin disease, such as melanoma, acquires images of a lesion on a subject's skin at different wavelengths and utilizes a sweeping arm rotating about the lesion in a clock-like sweep to produce diagnostically relevant metrics and classifiers from the image data so as to enhance detection of the skin disease.
Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods. This invention addresses the above-described un-met need by providing an immune complex (IC) or immune complexes (ICs), which take advantages of Type II Fc receptor (FcR) interactions and signaling to elicit broader and more potent protective immune responses. In one aspect, the invention provides an immune complex comprising an antigenic agent and an isolated protein. The protein comprises an IgG Fc region and is capable of binding to a Type II Fc receptor. Preferably, the protein is an antibody or an Fc region-containing fragment thereof.
Type:
Grant
Filed:
March 21, 2016
Date of Patent:
May 28, 2019
Assignee:
The Rockefeller University
Inventors:
Jeffrey V. Ravetch, Taia Wang, Jad Mamaary
Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
Abstract: Provided are compositions and methods useful in the diagnosis of Alzheimer's Disease (AD). The methods involve immunologically testing biological samples for an amount of high molecular weight kininogen (HK) and cleaved high molecular weight kininogen (HKc), wherein determining less HK relative to a normal control, or determining more HKc relative to a normal control, or a combination thereof, aids in diagnosis of AD. Hybridomas and monoclonal antibodies bind with specificity to either HK alone, or to both HK and HKc. Kits for use in immunological AD testing using the mAbs are also provided.
Abstract: The invention is directed to compositions and methods for treating or reducing the likelihood of the development of epilepsy in an individual. The method comprises administering to the central nervous system of an individual in need of such treatment a therapeutically effective amount of an agent capable of increasing the expression and/or activity of miR-128.
Type:
Application
Filed:
October 1, 2018
Publication date:
May 16, 2019
Applicants:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE ROCKEFELLER UNIVERSITY
Abstract: An optical system for the detection of skin disease, such as melanoma, acquires images of a lesion on a subject's skin at different wavelengths and utilizes a sweeping arm rotating about the lesion in a clock-like sweep to produce diagnostically relevant metrics and classifiers from the image data so as to enhance detection of the skin disease.
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.
Type:
Grant
Filed:
December 21, 2015
Date of Patent:
March 5, 2019
Assignee:
The Rockefeller University
Inventors:
Sohail Tavazoie, Nils Halberg, Masoud Tavazoie
Abstract: The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXR? agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.
Abstract: An optical system for the detection of skin disease, such as melanoma, acquires images of a lesion on a subject's skin at different wavelengths and utilizes a sweeping arm rotating about the lesion in a clock-like sweep to produce diagnostically relevant metrics and classifiers from the image data so as to enhance detection of the skin disease.
Abstract: The present invention provides STING crystals. The present invention also provides STING modulators that interact with sites present in and/or defined by such crystals. The present invention also provides methods of making and using such crystals and modulators. Other aspects and/or features of the present invention will be apparent to those skilled in the art, reading the present specification.
Type:
Grant
Filed:
July 31, 2014
Date of Patent:
January 8, 2019
Assignees:
Memorial Sloan-Kettering Cancer Center, The Rockefeller University, Rutgers, The State University of New Jersey, University of Bonn
Inventors:
Dinshaw J. Patel, Thomas Tuschl, Roger Jones, Gunther Hartmann, Winfried Barchet, Thomas Zillinger, Weiyi Wang, Pu Gao, Liang Deng, Manuel Ascano, Jr.
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
Abstract: The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.
Type:
Grant
Filed:
April 3, 2007
Date of Patent:
January 1, 2019
Assignee:
The Rockefeller University
Inventors:
Jeffrey V. Ravetch, Yoshikatsu Kaneko, Nimmerjahn Falk
Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
Type:
Grant
Filed:
December 8, 2017
Date of Patent:
November 20, 2018
Assignees:
Memorial Sloan Kettering Cancer Center, The Rockefeller University, Rutgers, The State University of New Jersey, University of Bonn
Inventors:
Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
Abstract: The invention is directed to compositions and methods for treating or reducing the likelihood of the development of epilepsy in an individual. The method comprises administering to the central nervous system of an individual in need of such treatment a therapeutically effective amount of an agent capable of increasing the expression and/or activity of miR-128.
Type:
Grant
Filed:
October 28, 2014
Date of Patent:
October 2, 2018
Assignees:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE ROCKEFELLER UNIVERSITY
Abstract: The present invention provides methods and compositions for the remote control of cell function based on the use of radiofrequency waves to excite nanoparticles targeted to specific cell types. The nanoparticles may be applied to the target cell extracellularly and/or expressed intracellularly. The cell type of interest expresses a temperature sensitive channel wherein excitation of the nanoparticles results in a localized temperature increase that is transduced into a cellular response. Such cellular responses may include, for example, increases in gene expression resulting in production of one or more physiologically active proteins. The expression of such proteins can be used to treat a variety of different inherited or acquired diseases or disorders in a subject. Accordingly, the invention provides a generic approach for treatment of any disease associated with a protein deficiency.
Abstract: A standardized, quantitative risk assessment method and apparatus for noninvasive melanoma screening. The apparatus and methods generate a melanoma Q-Score which calculates and displays a probability that a skin lesion is melanoma.
Abstract: The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.
Type:
Grant
Filed:
September 9, 2014
Date of Patent:
August 21, 2018
Assignee:
THE ROCKEFELLER UNIVERSITY
Inventors:
Vincent A. Fischetti, Anu Daniel, Chad Euler